# Bio-equivalence Study Between SAPHRIS and Asenapine

> **NCT01948024** · PHASE1 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 65 (actual)

## Conditions studied

- Schizophrenia
- Bipolar Disorder

## Interventions

- **DRUG:** SAPHRIS
- **DRUG:** Asenapine

## Key facts

- **NCT ID:** NCT01948024
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01948024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01948024, "Bio-equivalence Study Between SAPHRIS and Asenapine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01948024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*